Low-molecular-weight heparin use with thrombolysis: Is it effective and safe? ten years' clinical experience

Respiration

Volumn 86, Issue 4, 2013, Pages 318-323

  Ucar, Elif Yilmazel ^a   Araz, Omer ^a   Akgun, Metin ^a   Meral, Mehmet ^a   Kalkan, Fikriye ^a   Saglam, Leyla ^a   Kaynar, Hasan ^a   Gorguner, Ali Metin ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Acute pulmonary embolism; Low molecular weight heparin; Thrombolysis

Indexed keywords

ALTEPLASE; ENOXAPARIN; NADROPARIN; STREPTOKINASE; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GOOD CLINICAL PRACTICE; HEMOPERITONEUM; HEMOPTYSIS; HUMAN; IMMOBILITY; INTERNATIONAL NORMALIZED RATIO; INTRAMUSCULAR HEMORRHAGE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHOCK; TERTIARY HEALTH CARE; ACUTE RESPIRATORY FAILURE; ADVERSE OUTCOME; BLEEDING; DRUG USE; HOSPITALIZATION; MEDICAL RECORD REVIEW; OBESITY; TERTIARY CARE CENTER;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; TURKEY;

EID: 84888055816     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000346203     Document Type: Article

References (23)

1. Horlander KT, Mannino DM, Leeper KV: Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiplecause mortality data. Arch Intern Med 2003; 163: 1711.
2. Tapson VF: Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052.
3. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al: Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, ed 9. Chest 2012; 141:e419S-494S.
4. Quinlan DJ, McQuillan A, Eikelboom JW: Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a metaanalysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-183.
5. Erkens PM, Prins MH: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010; 9:CD001100.
6. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al, ESC Committee for Practice Guidelines (CPG): Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Eur Heart J 2008; 29: 2276-2315.
7. Akgun M, Meral M, Onbas O, Araz O, Koplay M, Aslan S, et al: Comparison of clinical characteristics and outcomes of patients with COPD exacerbation with or without venous thromboembolism. Respiration 2006; 73: 428-433.
8. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al: Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-1830.
9. Jerjes-Sánchez C, Villarreal-Umaña S, Ramírez-Rivera A, Garcia-Sosa A, Miguel-Canseco L, Archondo T, et al: Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. J Thromb Thrombolysis 2009; 27: 154-162.
10. Barritt DW, Jordan SC: Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1: 1309-1312.
11. Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI: Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010; 137: 1382-1390.
12. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA: Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157: 2562-2568.
13. Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
14. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M: Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971; 33: 616.
15. Thabut G, Thabut D, Myers RP, Bernard-Chabert B, Marrash-Chahla R, Mal H, et al: Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002; 40: 1660-1667.
16. Piazza G, Goldhaber SZ: Fibrinolysis for acute pulmonary embolism. Vasc Med 2010; 15: 419-428.
17. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749.
18. Kucher N, Rossi E, De Rosa M, Goldhaber SZ: Massive pulmonary embolism. Circulation 2006; 113: 577-582.
19. Cha SI, Shin KM, Lee JW, Lee J, Lee SY, Kim CH, et al: Clinical characteristics of patients with peripheral pulmonary embolism. Respiration 2010; 80: 500-508.
20. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W, Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators: Heparin plusalteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-1150.
21. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al: The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
22. van Beek EJ, Kuijer PM, Büller HR, Brandjes DP, Bossuyt PM, ten Cate JW: The clinical course of patients with suspected pulmonary embolism. Arch Intern Med 1997; 157: 2593-2598.
23. Meneveau N, Ming LP, Séronde MF, Mersin N, Schiele F, Caulfield F, et al: In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J 2003; 24: 1447-1454.